RenovoRx receives first purchase orders for FDA-cleared RenovoCath

RenovoRx (RNXT) announced that it has received its first purchase orders for RenovoCath devices. This milestone marks a positive continuation of RenovoRx’s previously announced efforts to commercialize RenovoCath as a standalone device to be used by doctors in accordance with its FDA-cleared instructions for use. RenovoCath is powered by the Company’s patented Trans-Arterial Micro-Perfusion therapy platform.